Indaptus Therapeutics Inc
For the period ended Jun 23, 2025. Filed Jun 23, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 23, 2025 · Filed Jun 23, 2025
Use the contents to explore the available documents and sections.
Contents
PROXY STATEMENT
This proxy statement is furnished in connection with the solicitation by the Board of Directors (the “Board” or “Board of Directors”) of Indaptus Therapeutics, Inc. of proxies to be voted at our Special Meeting of Stockholders to be held on July 25, 2025 (the “Special Meeting”), at 10:00 a.m. Eastern time, at the offices of Indaptus Therapeutics, Inc., 3 Columbus Circle, 15th Floor, New York, NY, and at any continuation, postponement, or adjournment of the Special Meeting.
Holders of record of shares of our common stock, $0.01 par value per share, as of the close of business on June 16, 2025 (the “Record Date”), will be entitled to notice of and to vote at the Special Meeting and any continuation, postponement, or adjournment of the Special Meeting. As of the Record Date, there were 16,034,444 shares of common stock outstanding and entitled to vote at the Special Meeting. Each share of common stock is entitled to one vote on any matter presented to stockholders at the Special Meeting.
This proxy statement will be released on or about July 1, 2025 to our stockholders on the Record Date.
In this proxy statement, “Indaptus”, “Company”, “we”, “us”, and “our” refer to Indaptus Therapeutics, Inc. (formerly Intec Parent, Inc.) and, where appropriate, its consolidated subsidiaries, Intec Pharma Ltd. and Decoy Biosystems, Inc. References to “Intec Parent” refer to Intec Parent, Inc., the successor of Intec Pharma Ltd. following the domestication merger (the “Domestication Merger”) with Intec Parent, references to “Intec Israel” refer to Intec Pharma Ltd., the predecessor of Indaptus prior to the Domestication Merger, and references to “Decoy” refer to Decoy Biosystems, Inc., the entity acquired by Indaptus in connection with the merger with Decoy.
IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDER MEETING TO BE HELD ON JULY 25, 2025
This Proxy Statement is available at http://www.proxyvote.com/
Proposals
At the Special Meeting, our stockholders will be asked:
| ● | To approve, in accordance with Nasdaq Listing Rule 5635(d), the issuance of (i) shares of the Company’s common stock issuable upon the conversion of convertible notes (“Notes”) issued or issuable in an ongoing private placement under Rule 506(c) of the Securities Act of 1933, as amended (the “Private Placement”), and (ii) shares of common stock issuable upon exercise of certain warrants including (“Common Warrants”) pre-funded warrants issuable in lieu of shares of common stock issuable upon conversion of the Notes (“Pre-funded Warrants”), and placement agent warrants (“Placement Agent Warrants”), each of which is issuable in the Private Placement (the “Issuance Proposal”); |
| ● | To approve, in accordance with Nasdaq Listing Rule 5635(c), the issuance of (i) shares of common stock issuable upon the conversion of one or more Notes issued or issuable in the Private Placement to the Chief Executive Officer and Director of the Company (“Related Party”), and (ii) shares of common stock issuable upon exercise of one or more Common Warrants issuable in the Private Placement to the Related Party (the “Related Party Proposal”); and |
| ● | To transact such other business as may properly come before the Special Meeting or any continuation, postponement, or adjournment of the Special Meeting. |
We know of no other business that will be presented at the Special Meeting. If any other matter properly comes before the stockholders for a vote at the Special Meeting, however, the proxy holders named on the Company’s proxy card will vote your shares in accordance with their best judgment.
Recommendations of the Board
The Board of Directors recommends that you vote your shares as indicated below. If you return a properly completed proxy card, or vote your shares by telephone or Internet, your shares of common stock will be voted on your behalf as you direct. If not otherwise specified, your shares of common stock represented by the proxies will be voted, and the Board of Directors recommends that you vote:
| ● | FOR the Issuance Proposal; and |
| ● | FOR the Related Party Proposal. |
If any other matter properly comes before the stockholders for a vote at the Special Meeting, the proxy holders named on the Company’s proxy card will vote your shares in accordance with their best judgment.
Information About This Proxy Statement
**Why you received this proxy statement.**You are viewing or have received these proxy materials because Indaptus’ Board of Directors is soliciting your proxy to vote your shares at the Special Meeting. This proxy statement includes information that we are required to provide to you under the rules of the SEC and that is designed to assist you in voting your shares.
**Printed Copies of Our Proxy Materials.**If you received printed copies of our proxy materials, then instructions regarding how you can vote are contained on the proxy card included in the materials.
**Householding.**The SEC rules permit us to deliver a single set of proxy materials to one address shared by two or more of our stockholders. This delivery method is referred to as “householding” and can result in significant cost savings. To take advantage of this opportunity, we have delivered only one set of proxy materials to multiple stockholders who share an address, unless we received contrary instructions from the impacted stockholders prior to the mailing date. We agree to deliver promptly, upon written or oral request, a separate copy of the proxy materials, as requested, to any stockholder at the shared address to which a single copy of those documents was delivered. If you prefer to receive separate copies of the proxy materials, contact Broadridge Financial Solutions, Inc. at 1-866-540-7095 or in writing at Broadridge, Householding Department, 51 Mercedes Way, Edgewood, New York 11717.
If you are currently a stockholder sharing an address with another stockholder and wish to receive only one copy of future proxy materials for your household, please contact Broadridge at the above phone number or address.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.